Navigation Links
Targeted Therapy Shows Promise Against Deadly Brain Cancer
Date:6/5/2010

Small trial found compound slowed drug-resistant medulloblastoma in children

SATURDAY, June 5 (HealthDay News) -- A preliminary study has found that a targeted treatment for medulloblastoma -- the most common malignant brain cancer in children -- may one day be able to treat drug-resistant forms of the disease.

"Less than 5 percent of patients currently survive medulloblastoma," said Dr. Amar Gajjar, lead author of the study, which was presented Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. "Most patients usually die 12 to 18 months after the tumor comes back."

Although this study was designed primarily to assess side effects, if the drug moves through the pharmaceutical pipeline, it would be the first targeted drug aimed at a signaling pathway. Chemotherapy is the main treatment now.

The drug, known as GDC-0449, interrupts the "sonic hedgehog" pathway, which has been implicated in a number of other cancers; it is involved in 20 percent of cases of children with medulloblastoma.

The drug has already been shown to have some effectiveness in adults with medulloblastoma that has recurred, as well as with basal cell carcinoma, a type of skin cancer.

Thirteen children with recurrent or drug-resistant brain tumors took GDC-0449 once a day for 28 days at one of two doses. The median age of the participants was about 12.

Twelve of the participants stayed the course without major side effects. One child was able to continue taking the drug for a full year without the cancer progressing.

"This demonstrates that we have taken a tumor, found a molecular subtype, found a drug which works, showed that it's safe in children and that we can have them benefit by treating these tumors using this molecular targeted therapy," said Gajjar, who is director of neuro-oncology in the department of oncology at St. Jude Children's Research Hospital in Memphis.

The research group will be moving on to a phase 2 trial. A phase 2 trial in adults is already ongoing, Gajjar said.

"Preliminary analysis has shown benefits to these [adult] patients," he noted.

Because this was such an early trial, "we don't yet know what impact this drug is going to have on survival," said Dr. Lynn Schuchter, moderator of a news conference involving the trial and a professor of medicine at the Abramson Cancer Center at the University of Pennsylvania. "We don't have a lot of data on follow-up, but this is really an amazing proof-of-principle idea and this pathway looks to be relevant in many cancers."

Schuchter reported ties to drug maker Pfizer Inc., while Gajjar reported no such ties.

More information

Children's Hospital Boston has more on medulloblastoma.



SOURCES: June 5, 2010, news conference with Lynn Schuchter, M.D., professor, medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, and Amar Gajjar, M.D., director, neuro-oncology division, department of oncology, St. Jude Children's Research Hospital, Memphis, Tenn.; June 5, 2010, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Targeted Radiation for Early Breast Cancer a Good Option: Study
2. Blocking DNA repair protein could lead to targeted, safer cancer therapy
3. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
4. Women Smokers Targeted on World No Tobacco Day
5. Drug in new class of targeted therapies shows early promise against blood-related cancers
6. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
7. Gene-Targeted Therapy Might Help Prevent Paralysis
8. New targeted therapy effective in treating advanced prostate cancer
9. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
10. Targeted agent blocked growth of deadly brain cancer in preclinical studies
11. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology: